Supriya LifescienceQ1 FY25

Supriya Lifescience Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹620.65P/E: 28.1Market Cap: ₹5.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • The Company anticipates significant future growth driven by new product launches, especially in anesthetics, antidiabetics, and antianxiety therapeutic areas, targeting larger global markets.
  • Expansion and ramp-up of Module E will double total capacity to 1,020 KL by September, supporting higher volumes.
  • CDMO and CMO business contributions expected to start by Q3 FY25, targeting around 20% of total revenue in the next 3-4 years.
  • Increased presence in regulated markets like Europe, North America, and Latin America expected to boost revenue with higher-margin opportunities.
  • Brazil and Mexico markets offer good opportunity due to new GMP certification ultimatum effective by December 2024, driving increased basket and revenue.
  • Oral cancer kit commercialization and patent approvals are anticipated in 1-1.5 years, with revenue contributions expected in the coming quarters but full-scale commercial production over 2 years.
  • Overall EBITDA margins expected to remain trending upwards, with margin normalization around 28-30% as new products scale.

See what Supriya Lifescience management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • No mention of any current or future fundraising through debt or equity was made in the transcript.
  • The company maintains a very strong financial position with a very low debt-to-equity ratio of 0.01.
  • The company follows a conservative borrowing approach, utilizing only letters of credit and bank guarantees without tapping into working capital limits.
  • Capital expenditure plans, such as the Rs. 75-78 crore allocated for the Ambernath facility, are being funded internally without reference to new fundraising.
  • Overall, the company appears focused on organic growth and internal cash flow for funding expansions rather than raising fresh debt or equity.

See what Supriya Lifescience management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Ambernath facility CapEx is currently around Rs. 75-78 crores, down from an initial Rs. 100 crores allocation for FY25.
  • Ambernath facility is under validation; production expected to start partially within 60 days.
  • Ambernath focuses on CMO/CDMO, with multiple lines for injectables, tablets, capsules, plus R&D for contract research and API development.
  • Module E expansion will add 500 KL capacity, doubling total capacity to 1,020 KL by end of September 2024.
  • New product launches and capacity ramp-up are key catalysts for growth, indicating ongoing strategic investments.
  • No current contribution from CMO/CDMO, but expected to reach ~20% of revenue within 3-4 years.

Track Supriya Lifescience — get its next earnings analysis in your feed

How does Supriya Lifescience rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSupriya Lifescience
Rev 2Mar 1

How does Supriya Lifescience rank in Pharmaceuticals & Biotechnology?

Compare Supriya Lifescience against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →